5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.46▲ | 1.47▼ | 1.48▼ | 1.52▼ | 1.86▼ |
MA10 | 1.47▼ | 1.48▼ | 1.47▼ | 1.67▼ | 2.58▼ |
MA20 | 1.48▼ | 1.47▼ | 1.47▼ | 2.01▼ | 4.73▼ |
MA50 | 1.47▼ | 1.55▼ | 1.60▼ | 2.82▼ | 12.27▼ |
MA100 | 1.52▼ | 1.70▼ | 1.82▼ | 5.57▼ | 20.36▼ |
MA200 | 1.65▼ | 2.02▼ | 2.62▼ | 10.98▼ | 38.38▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.003▼ | 0.006▲ | 0.011▲ | 0.006▲ | 0.148▲ |
RSI | 45.287▼ | 41.387▼ | 37.943▼ | 25.833▼ | 30.592▼ |
STOCH | 15.417▼ | 38.856 | 56.250 | 6.159▼ | 1.836▼ |
WILL %R | -87.500▼ | -77.778▼ | -43.750 | -92.973▼ | -98.805▼ |
CCI | -70.922 | -60.425 | -14.902 | -110.500▼ | -119.621▼ |
Wednesday, June 18, 2025 04:47 PM
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the ...
|
Monday, June 02, 2025 09:05 AM
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that ...
|
Tuesday, April 29, 2025 11:03 PM
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) stock is up 676.99% year-to-date. Overall, XFOR ranks 2nd on our list of healthcare stocks that are surging in 2025.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/07/25 | 1.475 | 1.50 | 1.455 | 1.465 | 351,000 |
14/07/25 | 1.43 | 1.49 | 1.40 | 1.48 | 408,500 |
11/07/25 | 1.56 | 1.56 | 1.41 | 1.43 | 645,400 |
10/07/25 | 1.66 | 1.7299 | 1.545 | 1.57 | 580,399 |
09/07/25 | 1.70 | 1.79 | 1.63 | 1.66 | 594,600 |
08/07/25 | 1.72 | 1.799 | 1.64 | 1.665 | 477,400 |
07/07/25 | 1.88 | 1.93 | 1.68 | 1.685 | 562,789 |
03/07/25 | 2.00 | 2.028 | 1.85 | 1.89 | 377,237 |
02/07/25 | 1.91 | 2.12 | 1.88 | 1.98 | 701,300 |
01/07/25 | 1.93 | 1.93 | 1.82 | 1.86 | 407,300 |
|
|
||||
|
|
||||
|
|